Nova recalls StatStrip glucose meters in Class I action over barcode mix-ups

Nova Biomedical is recalling one of the workhorses of hospital diabetes care: the bedside glucose meter. The Food and Drug Administration recorded the action in its enforcement database on 23 September 2026 and classified it as Class I — the agency's most serious recall category, used where a defect could cause serious injury or death [s1]. The product named is the StatStrip Glucose and B-Ketone meter, Model 63910, described in the record as a glucose test system [s1].

What is affected

The recall covers 8,939 units distributed worldwide — across the United States and 22 other countries including Canada, the United Kingdom, Germany, France, Italy, Brazil and South Korea [s1]. The affected devices carry UDI-DI 00385480639101 and run software versions 0.00.13.10 through 1.5.14.25 [s1]. Nova Biomedical, based in Waltham, Massachusetts, began the recall itself on 29 July 2026, making this a voluntary, firm-initiated action, and the FDA lists its status as ongoing [s1].

Why a barcode flaw matters

The defect is not in the chemistry. The enforcement record states plainly that it "does not affect the analytical accuracy of glucose measurements" [s1]. The problem is in how the meter handles identity. A timing fault in the barcode-scanning and patient-data component can cause the device to hold on to a previously scanned barcode — including a patient identification barcode or a quality-control solution barcode — when a new one is scanned, so the earlier information stays on screen for the current test [s1].

If an operator accepts that stale information without catching the mismatch, the consequences cascade. The current patient's glucose result is filed to the previous patient's medical record and sent on to the data-management system, while the current patient's own record receives no result at all, leaving their glucose status unrecorded [s1]. The earlier patient, whose chart now holds a reading that is not theirs, "may receive inappropriate clinical intervention based on that erroneous result" — a risk the record singles out as sharpest in critically ill patients, neonates and infants who cannot flag symptoms or self-treat [s1]. The same retention behaviour can also misattribute quality-control results or make QC tests fail without the user understanding why [s1].

The wider context

Point-of-care glucose meters sit at the centre of inpatient diabetes management, used many times a day across wards, intensive care and neonatal units to steer insulin dosing. The StatStrip line is cleared in the United States as a clinical-chemistry device; the StatStrip Glucose Hospital Meter System was granted FDA clearance under 510(k) K232075 on 23 February 2024 [s2]. A glucose value that is accurate in isolation but attached to the wrong name is, in that setting, a patient-safety hazard rather than a laboratory one — which is why the agency applied its top classification to a software timing fault rather than a chemistry error [s1].

The scale is wide but not unbounded. The 8,939 units reach the United States and 22 other countries, a worldwide footprint that turns a single software fault into a coordinated correction across health systems that each handle patient identity differently [s1]. That the record pins the risk to the handful of seconds when an operator reads the screen and confirms a result is a reminder that bedside testing depends as much on the device's interface as on its chemistry: the moment of identification is where the error hides [s1].

What to do

This is a recall aimed at hospitals and clinical laboratories, not at home testers; the Model 63910 is a professional hospital meter rather than a consumer fingerstick device [s1][s2]. For the biomedical, laboratory and nursing teams who operate these meters, a Class I recall sets a practical task: identify whether any affected units running the listed software versions are in use, and follow Nova Biomedical's correction instructions for the fix or update [s1].

Red flags worth raising with a care team include a glucose result that does not match a patient's clinical picture, a reading that appears under the wrong name, or a record showing no result when a test was clearly performed [s1]. People living with diabetes who use their own meters at home are not covered by this action, but anyone unsure whether a device they rely on is affected can check the model and UDI against the agency's enforcement record.

This article describes an FDA enforcement action and is not medical advice. Questions about a glucose reading, an insulin dose or any recall affecting a particular course of treatment are for the treating clinicians and the hospital's laboratory team, who can check device models and software versions against the agency's record.

Sources

• FDA Enforcement Report Z-3131-2026: Nova Biomedical StatStrip Glucose and B-Ketone meter, Model 63910 — U.S. Food and Drug Administration, report date 23 September 2026
• 510(k) K232075: StatStrip Glucose Hospital Meter System, Nova Biomedical Corporation — U.S. Food and Drug Administration, decision date 23 February 2024